ZYBERNO
Stock Report
Updated Aug 31, 2026

RALLYBIO CORPORATION (RLYB)

Healthcare • NASDAQ

$16.53

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
43.0/100
WEAK BUSINESS
RALLYBIO CORPORATION (RLYB) scores 43/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):EXCELLENT (68.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (-4,291.5%)
Return on Capital (Capital Efficiency):CRITICAL (-1,633.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

RALLYBIO CORPORATION (RLYB) stock report — Zyberno Score 43/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RLYB generated -$60.28M in Owner Earnings. Capital was deployed as follows: $12.00K invested in capital expenditures. Reinvestment rate: 0.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:16.53
Market Cap:$94.21M

Valuation Multiples (4)

P/B Ratio:1.00x
P/S Ratio:145.83x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.36M

Price Action & Momentum (3)

Momentum Percentile:99 / 100
% of 52-Week High:94.1%
B. Profitability Assessment

Return Metrics (5)

ROA:64.5%
Reinvestment Rate:0.3%
Fundamental Growth Rate (g):-5.6%

Margin Analysis (3)

Operating Margin Ttm:-4,291.5%
Net Margin Ttm:7,051.2%
Ebitda Margin:-4,281.1%

TTM Performance (2)

Operating Margin Ttm:-4,291.5%
Net Margin Ttm:7,051.2%

Yield Metrics (2)

Earnings Yield:$28.95
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:6,055.9%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-19.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:27.26x
Quick Ratio:27.26x
Cash Ratio:26.03x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:93,686,000.00
Cash And Cash Equivalents:92,849,000.00
Long Term Debt:$0.00
Net Debt:-$92.85M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $646.00K
Linear Growth: -19.2%
📊 Click to view full RLYB Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$27.72M

Bottom Line Performance (3)

$45.55M
Income Before Tax:$46.88M
Ebitda Ttm:-27,656,000.00

Operating Expenses (5)

Operating Expenses:28,369,000.00
R And D Expense:11,427,000.00
Sga Expense:16,942,000.00
Income Tax Expense:$1.32M
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-4,281.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$98.06M
Current Assets:$97.25M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,567,000.00
Current Liabilities:3,567,000.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$94.50M
Retained Earnings:-$266.61M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:833,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:424,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$27.59M-$27.60M

Investment Activities (2)

Investing Cash Flow:$17.90M
Capital Expenditures Ttm:12,000.00

Financing Activities (3)

Financing Cash Flow:$3.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:3,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:67,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):5.04
$4.91
Earnings Per Share Ttm:$7.99

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.11
Operating Cash Flow Per Share:-$5.23

Book Value & Capital (2)

Book Value Per Share:$16.58
Cash Per Share:16.29

Dividend Policy (1)

Dividend Payout Ratio:0.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.01x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:470.66
Cash Conversion Cycle:-2,468.66
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$60.28M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.3%
Fundamental Growth Rate (g):-5.6%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-19.2%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-24.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:RLYB
Company Name:RALLYBIO CORPORATION
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:5.70M
Shares Outstanding Basic:5.70M
Shares Outstanding Diluted:5.80M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 19:12:40 UTC
Data Timestamp:2026-08-19T19:13:46.868629
Scroll to Top